In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global en ...

The stock's fall snapped a two-day winning streak.

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with other layoffs elsewhere.